OncoDaily IO

Mario Balsa Explores Infusion Timing and Survival Outcomes With Anti-PD-1 @MarioBalsaMD #OncoDaily" target="_blank" rel="nofollow noopener">oncodaily.com/science/mario-…

Fear Shouldn’t Drive Decisions, Facts Should - Ganesh S. Jaishetwar @GJaishetwar oncodaily.com/voices/ganesh-…

🧬 𝗖𝗮𝗻 𝗠𝗶𝗻𝗶𝗺𝗮𝗹 𝗥𝗡𝗔 𝗥𝗲𝗱𝗲𝗳𝗶𝗻𝗲 𝗣𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘇𝗲𝗱 𝗖𝗮𝗻𝗰𝗲𝗿 𝗩𝗮𝗰𝗰𝗶𝗻𝗲𝘀? oncodaily.com/oncolibrary/im… A new study in Nature Biomedical Engineering introduces ChemRNA—a chemically synthesized minimal RNA platform that generates potent antigen-specific CD8⁺ T-cell responses without the canonical 5′ cap, poly(A) tail, or untranslated regions. 📊 𝗞𝗲𝘆 𝗳𝗶𝗻𝗱𝗶𝗻𝗴𝘀: ▪️ Robust MHC-I antigen presentation and CD8⁺ T-cell activation ▪️ Antitumor activity comparable to conventional IVT mRNA in preclinical models ▪️ Simplified chemical synthesis without DNA templates, capping, or polyadenylation ▪️ Potential to accelerate and reduce the cost of personalized neoantigen vaccine manufacturing 💡 If validated clinically, ChemRNA could represent a new generation of RNA-based cancer vaccines.

Raghu Kalluri on CDK8 as a Resistance Mechanism Across KRAS Inhibitors @rkalluriMDPhD oncodaily.com/voices/raghu-k…

Mario Balsa on 4-1BB⁺ CD4 T Cells in Long-Term Melanoma Survivors @MarioBalsaMD oncodaily.com/science/mario-…

🧬 10 Must-Read Posts in Immuno-Oncology This Week This week’s OncoDaily IO roundup features the latest advances in AI, cancer vaccines, CAR-T therapy, immune engineering, and recent FDA approvals shaping the future of immunotherapy. oncodaily.com/oncolibrary/im…

🟠 𝗙𝗗𝗔 𝗔𝗽𝗽𝗿𝗼𝘃𝗲𝘀 𝗣𝗲𝗿𝗶𝗼𝗽𝗲𝗿𝗮𝘁𝗶𝘃𝗲 𝗣𝗲𝗺𝗯𝗿𝗼𝗹𝗶𝘇𝘂𝗺𝗮𝗯 + 𝗘𝗻𝗳𝗼𝗿𝘁𝘂𝗺𝗮𝗯 𝗩𝗲𝗱𝗼𝘁𝗶𝗻 𝗳𝗼𝗿 𝗠𝘂𝘀𝗰𝗹𝗲-𝗜𝗻𝘃𝗮𝘀𝗶𝘃𝗲 𝗕𝗹𝗮𝗱𝗱𝗲𝗿 𝗖𝗮𝗻𝗰𝗲𝗿 The U.S. FDA has approved pembrolizumab (Keytruda/Keytruda Qlex) + enfortumab vedotin (Padcev) as perioperative therapy for adults with muscle-invasive bladder cancer (MIBC) undergoing radical cystectomy. The approval expands the regimen to all patients eligible for radical cystectomy, regardless of cisplatin eligibility. 📊 𝗞𝗲𝘆 𝗞𝗘𝗬𝗡𝗢𝗧𝗘-𝗕𝟭𝟱/𝗘𝗩-𝟯𝟬𝟰 𝗿𝗲𝘀𝘂𝗹𝘁𝘀: ▪️ 47% reduction in the risk of recurrence, progression, or death (EFS HR 0.53) ▪️ 35% reduction in the risk of death (OS HR 0.65) ▪️ Median EFS: Not reached vs 48.5 months with neoadjuvant gemcitabine/cisplatin 💡 This approval establishes a new perioperative standard, bringing PD-1 blockade plus a Nectin-4–targeted ADC into curative-intent treatment for localized bladder cancer. 🖇️oncodaily.com/oncolibrary/im…

🚨 𝗙𝗗𝗔 𝗜𝗺𝗺𝘂𝗻𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗔𝗽𝗽𝗿𝗼𝘃𝗮𝗹𝘀: 𝗙𝗶𝗿𝘀𝘁 𝗛𝗮𝗹𝗳 𝗼𝗳 𝟮𝟬𝟮𝟲 The first half of 2026 marked another major step forward for immuno-oncology, with 10 new FDA approvals expanding immune-based therapies across hematologic malignancies and solid tumors. 🔬 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: 🩸 Multiple Myeloma ▪️ Daratumumab + VRd (CEPHEUS) ▪️ Teclistamab + Daratumumab (MajesTEC-3) 🧬 Stem Cell Transplantation ▪️ Tregzi (Precision-T) — first FDA-approved allogeneic regulatory T-cell therapy 🫁 Classical Hodgkin Lymphoma ▪️ Nivolumab + AVD (SWOG S1826) 🎗️ Triple-Negative Breast Cancer ▪️ Sacituzumab Govitecan (ASCENT-03) ▪️ Sacituzumab Govitecan + Pembrolizumab (ASCENT-04/KEYNOTE-D19) 🟢 Renal Cell Carcinoma ▪️ Belzutifan + Pembrolizumab (LITESPARK-022) 💙 Bladder Cancer ▪️ Durvalumab + BCG (POTOMAC) ▪️ Atezolizumab (IMvigor011) — first ctDNA-guided immunotherapy after cystectomy 🌸 Platinum-Resistant Ovarian Cancer ▪️ Pembrolizumab + Paclitaxel ± Bevacizumab (KEYNOTE-B96) 💡 From cellular therapies and bispecific antibodies to ADCs and biomarker-driven immunotherapy, these approvals continue to redefine the standard of cancer care. 🔗 Read the full article: oncodaily.com/oncolibrary/im…

Yan Leyfman, MD Leyfman on CAR T-Cell Resistance and the Tumor Microenvironment @YLeyfman oncodaily.com/voices/yan-ley…

🧬 𝗪𝗛𝗢 𝗚𝗹𝗼𝗯𝗮𝗹 𝗖𝗮𝗻𝗰𝗲𝗿 𝗥𝗲𝗽𝗼𝗿𝘁 𝟮𝟬𝟮𝟲: 𝗜𝗺𝗺𝘂𝗻𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗜𝘀 𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗶𝗻𝗴 𝗖𝗮𝗻𝗰𝗲𝗿 𝗖𝗮𝗿𝗲, 𝗕𝘂𝘁 𝗔𝗰𝗰𝗲𝘀𝘀 𝗥𝗲𝗺𝗮𝗶𝗻𝘀 𝘁𝗵𝗲 𝗕𝗶𝗴𝗴𝗲𝘀𝘁 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲 The WHO Global Status Report on Cancer 2026 highlights immunotherapy as one of the greatest advances in modern oncology. Immune checkpoint inhibitors have transformed outcomes across multiple cancers, while the next generation of innovation continues to expand. 🧬 𝗧𝗵𝗲 𝗻𝗲𝘅𝘁 𝘄𝗮𝘃𝗲 𝗶𝗻𝗰𝗹𝘂𝗱𝗲𝘀: ▪️ Antibody-drug conjugates (ADCs) ▪️ Therapeutic cancer vaccines ▪️ AI and multi-omics ▪️ Genomic profiling and liquid biopsy Yet the report delivers a powerful message: Scientific breakthroughs alone will not solve the global cancer burden. Millions of patients still lack access to the diagnostics, medicines, pathology services, radiotherapy, surgery, and healthcare systems needed to benefit from modern cancer treatment. 💡 The future of immuno-oncology depends not only on innovation—but on equitable access to that innovation. @WHO 🔗 Read the full article: oncodaily.com/oncolibrary/im…

🎙️ 𝗘𝘅𝗰𝗹𝘂𝘀𝗶𝘃𝗲 𝗢𝗻𝗰𝗼𝗗𝗮𝗶𝗹𝘆 𝗜𝗢 𝗜𝗻𝘁𝗲𝗿𝘃𝗶𝗲𝘄 We spoke with @Brunet3Leon about the biological and clinical implications of the PACIFIC post-hoc analysis, exploring how proton pump inhibitors, antibiotics, and the gut microbiome may influence the efficacy of consolidation durvalumab in unresectable stage III NSCLC. 🧬 The discussion covers: ▪️ Why PPIs and antibiotics may affect immunotherapy outcomes ▪️ The role of the gut microbiome in anti-tumor immunity ▪️ Clinical implications for medication stewardship ▪️ Future directions for microbiome-guided precision immunotherapy 📖 Read the full interview to discover how supportive medications and the microbiome could help shape the next generation of personalized immunotherapy.

University of Pennsylvania - CAR T Cell Therapy Leads to 10-Year Remissions in B-Cell Lymphoma Patients @Penn oncodaily.com/voices/univers…

🧬 𝗖𝗮𝗻 𝗔𝗜 𝗣𝗿𝗲𝗱𝗶𝗰𝘁 𝗜𝗺𝗺𝘂𝗻𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗥𝗲𝘀𝗽𝗼𝗻𝘀𝗲 𝗔𝗰𝗿𝗼𝘀𝘀 𝗠𝘂𝗹𝘁𝗶𝗽𝗹𝗲 𝗖𝗮𝗻𝗰𝗲𝗿𝘀? oncodaily.com/oncolibrary/im… A new study introduces COMPASS, an AI foundation model trained on transcriptomic data to predict responses to immune checkpoint inhibitors across multiple tumor types. 📊 𝗞𝗲𝘆 𝗳𝗶𝗻𝗱𝗶𝗻𝗴𝘀: ▪️ Outperformed conventional transcriptomic biomarkers across multiple validation cohorts ▪️ Accurately predicted immunotherapy response in NSCLC, melanoma, RCC, urothelial carcinoma, and other solid tumors ▪️ Identified response-associated programs (interferon signaling, T-cell activation) and resistance pathways (angiogenesis, stromal remodeling, hypoxia) ▪️ Generated patient-specific biological insights beyond PD-L1 and TMB 💡 COMPASS highlights the potential of AI-driven precision immuno-oncology to improve patient selection and move beyond single biomarker–based treatment decisions.

Rewiring CAR T-Cell Signaling to Overcome Immune Suppression in Solid Tumors - Yan Leyfman, MD @YLeyfman oncodaily.com/voices/yan-ley…

Immunotherapy Moves Into the Curative Setting for Stage III dMMR Colon Cancer – Immune Oncology Research Institute @ImmoncInstitute oncodaily.com/voices/immunot…

Panel Discussion: Next Generation Immuno-Oncology Platforms Driving Innovation – Society for Immunotherapy of Cancer (SITC) @sitcancer oncodaily.com/voices/immuno-…

A Guide to CAR T Cell Therapy - Hind Rafei (@HindRafei) oncodaily.com/voices/hind-ra…

Episode 5 of CAR-T Physiology Pearls Focuses on Ferritin - Dr. Aishee Pal Sadhu, M.D., AIIMS Delhi @ActImmuno oncodaily.com/voices/aishee-…